Abstract |
Metastatic pancreatic ductal adenocarcinomas (PDACs) are now more effectively controlled using chemotherapy combinations such as FOLFIRINOX and gemcitabine plus nab-paclitaxel (NabP) regimens with a subset of patients who achieve a sustained tumor stabilization or response. The next challenge is to design maintenance therapies that result in continued tumor control with minimal toxicity. Quality of life should always be a priority in these patients with prolonged survival. Gradually tapering off the intensity of chemotherapy by suppressing drug(s) in the combination is one option. Thus, maintenance with 5-fluorouracil or gemcitabine as single agents after FOLFIRINOX or gemcitabine-NabP induction, respectively, seems to be a promising approach to minimize neurotoxicity while maintaining efficacy. Another option is to introduce maintenance drug(s) with different anti-tumoral actions. The recent example of olaparib in patients with BRCA mutated PDAC provides a promising proof-of-concept of a switch maintenance strategy in this setting.
|
Authors | Pascal Hammel, Carole Vitellius, Émeric Boisteau, Mathilde Wisniewski, Elise Colle, Marc Hilmi, Christelle Dengremont, Sandra Granier, Anthony Turpin, Louis de Mestier, Cindy Neuzillet |
Journal | Therapeutic advances in medical oncology
(Ther Adv Med Oncol)
Vol. 12
Pg. 1758835920937949
( 2020)
ISSN: 1758-8340 [Print] England |
PMID | 32695234
(Publication Type: Journal Article, Review)
|
Copyright | © The Author(s), 2020. |